Stock TENX TENAX THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Tenax Therapeutics, Inc.

Equities

TENX

US88032L6056

Delayed Nasdaq
Other stock markets
 11:20:10 2024-04-18 am EDT 		5-day change 1st Jan Change
3.58 USD -0.28% Intraday chart for Tenax Therapeutics, Inc. -7.49% -83.70%
Mar. 28 Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 28 Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”
AQ
Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results
AQ
Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Tenax Therapeutics to Present at the 36th Annual Roth Conference
AQ
Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024
AQ
Tenax Therapeutics Secures Global Rights for Levosimendan
MT
Tenax Therapeutics, Inc. and Orion Corporation Enters into an Amendment to Certain License Agreement
CI
Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan
AQ
Top Midday Decliners
MT
Wall Street Set to Open Flat Wednesday; Jobless Claims Fall More Than Expected
MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday as Investors Await Economic Data
MT
Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering
AQ
US Futures Marginally Lower Ahead of Jobless Claims, Wholesale Trade Data
MT
Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
AQ
Tenax Therapeutics Enrolls First Patient in Phase 3 Level Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in PH-HFpEF Patients
CI
Sector Update: Health Care Stocks Gain Late Afternoon
MT
Sector Update: Health Care
MT
Top Midday Gainers
MT
Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TENX Stock
  4. News Tenax Therapeutics, Inc.